Skip to main content

Table 2 Comparison of individuals with CDI identified by laboratory dataset versus hospitalization admission and discharge database (DAD) among those with and without IBD

From: Effect of clinical versus administrative data definitions on the epidemiology of C. difficile among hospitalized individuals with IBD: a population-based cohort study

 

IBD

Individuals without IBD

CDI identified by laboratory dataset

CDI identified by DAD

p value

CDI identified by laboratory dataset

CDI identified by DAD

p value

(n = 108)

(n = 110)

 

(n = 226)

(n = 201)

 

Age Median (IQR)

55.5(34–75)

60 (40–75)

0.49

74.5 (63–82)

72 (61–82)

0.38

% CD

51

46

0.59

   

% Male

44

47

0.59

43

42

0.77

Use 1 year prior

      

5-ASA use (%)

47.2

51.8

0.50

   

Thiopurine use (%)

19.4

16.4

0.60

   

Anti-TNF use (%)

7.4

10.9

0.48

   

Corticosteroid use (%)

45.4

40.9

0.58

   

Use 3 month prior

      

Any antibiotic use (%)

50.0

50.9

1

50.0

49.2

0.92

Ciprofloxacin use (%)

16.7

16.4

1

19.9

17.9

0.62

Metronidazole use (%)

17.6

16.4

0.86

8.0

9.0

0.73

Clindamycin use (%)

Data too sparse to report N < 6

Data too sparse to report N < 6

1

6.6

7.0

1

Hospitalization in the prior year (%)

62

63.6

0.89

56.2

55.7

0.92

Surgery (%)

23.2

20

0.62

Data too sparse to report N < 6

3.0

0.76

Charlson comorbidity index score (%)

  

0.41

  

0.90

 0

49.1

42.7

 

22.6

19.9

 

 1

16.7

20

 

18.1

19.4

 

 2

21.3

17.3

 

18.6

17.9

 

 3+

13

20

 

40.7

42.8

 

Ambulatory care (%)

  

0.98

  

0.87

 Lowest quartile

11.1

10

 

15.5

15.9

 

 2nd quartile

15.7

14.6

 

25.2

23.9

 

 3rd quartile

34.3

34.6

 

21.7

24.9

 

 Highest quartile

38.9

40.9

 

37.6

35.3

 
  1. aAmbulatory care frequency quartiles: Quartile 1 0–8, Quartile 2 9–16, Quartile 3 17–27, Quartile 4 28 +